A Phase 1b/2a Randomized, Open-label Clinical Trial of Daily Myrcludex B Versus Entecavir in Patients With HBeAg Negative Chronic Hepatitis B

Trial Profile

A Phase 1b/2a Randomized, Open-label Clinical Trial of Daily Myrcludex B Versus Entecavir in Patients With HBeAg Negative Chronic Hepatitis B

Completed
Phase of Trial: Phase I/II

Latest Information Update: 13 Sep 2016

At a glance

  • Drugs Myrcludex-B (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Hepatera
  • Most Recent Events

    • 11 Mar 2014 Status changed from recruiting to active, no longer recruiting based on information reported in a Hepatera media release.
    • 06 Mar 2014 Preliminary results are expected in June 2014 according to a Hepatera media release.
    • 21 Dec 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top